Control of the cell survival/death decision by cannabinoids

Journal of Molecular Medicine

Volumn 78, Issue 11, 2001, Pages 613-625

  Guzmán, Manuel ^a   Sánchez, Cristina ^a   Galve Roperh, Ismael ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Apoptosis; Cancer; Cannabinoids; Cell proliferation; Neuroprotection

Indexed keywords

ADAPTOR PROTEIN; CANNABINOID; CANNABINOID RECEPTOR; GLUTAMATE RECEPTOR; NEUROPROTECTIVE AGENT;

APOPTOSIS; CELL DEATH; CELL FATE; CELL SURVIVAL; CELL TRANSFORMATION; DRUG DELIVERY SYSTEM; GLIOMA; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; NERVE CELL; PROSTATE CANCER; REVIEW; STROKE;

EID: 0034467577     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090000177     Document Type: Review

References (114)

1. Isolation, structure and partial synthesis of an active constituent of hashish
2. 2 receptors
3. Determination and characterization of a cannabinoid receptor in rat brain
4. Structure of a cannabinoid receptor and functional expression of the cloned cDNA
5. Molecular characterization of a peripheral receptor for cannabinoids
6. Cannabinoid receptors
7. Cannabinoid receptor agonists and antagonists
8. 2, a peripheral cannabinoid receptor
9. 2 receptor
10. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker
11. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
12. 2 cannabinoid receptor
13. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
14. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor
15. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors
16. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain
17. Formation and inactivation of endogenous cannabinoid anandamide in central neurons
18. A second endogenous cannabinoid that modulates long-term potentiation
19. Functional role of high-affinity anandamide transport, as revealed by selective inhibition
20. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist
21. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
22. Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action
23. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds
24. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide
25. 1
26. 2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression
27. 1 cannabinoid receptors in human vascular endothelial cells
28. 1 cannabinoid receptor is coupled to the action of c-Jun N-terminal kinase
29. 1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt
30. 9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes
31. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation
32. Regulation of ceramide production and apoptosis
33. Interactive effects of nutrition and cannabis upon rat perinatal development
34. Developmental aspects of anandamide: Ontogeny of response and prenatal exposure
35. Perinatal exposure to cannabinoids alters neurochemical development in the rat brain
36. The endogenous cannabinoid system and brain development
37. 9-Tetrahydrocannabinol induces apoptosis in C6 glioma cells
38. Anandamide induces apoptosis of PC-12 cells: Involvement of superoxide and caspase-3
39. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors
40. 9-tetrahydrocannabinol
41. 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice
42. Neurotoxicology of cannabis and THC: A review of chronic exposure studies in animals
43. Does ceramide play a role in neural cell apoptosis?
44. Pathobiology of ischaemic stroke: An integrated view
45. The endocannabinoid system as a target for therapeutic drugs
46. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures
47. 2-weighted magnetic resonance imaging
48. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons
49. Cannabinoid receptor agonist protect cultured rat hippocampal neurons from excitotoxicity
50. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats
51. Cannabidiol and delta-9-tetrahydrocannabinol are neuroprotective antioxidants
52. Cannabinoids protect cells from oxidative cell death: A receptor independent mechanism
53. Cannabinoid receptor agonist inhibit glutamatergic synaptic transmission in rat hippocampal cultures
54. Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons
55. 2+ current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism
56. Cannabinoids inhibit N-type calcium channels in neuroblastomaglioma cells
57. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons
58. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission
59. 2+ signals in cerebellar granule neurons in culture
60. Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes
61. Gap-junction-mediated propagation and amplification of cell injury
62. Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells
63. The stimulation of ketogenesis by cannabinoids in cultured astrocytes defines carnitine palmitoyltransferase I as a new ceramide-activated enzyme
64. Formation of N-acyl phosphatidylethanolamines and N-acyl ethanolamines. Proposed role in neurotoxicity
65. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
66. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease
67. 1 cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity
68. Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes
69. Effect of cannabinoids on energy metabolism
70. Pyruvate and lactate protect striatal neurons against N-methyl-D-aspartate-induced neurotoxicity
71. D-Beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease
72. Cannabis and recurrent herpes simplex
73. Drugs and immunity: Cannabinoids and their role in decreased resistance to infectious disease
74. Cannabinoid receptors and immunity
75. Anadamide, an endogeonous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis
76. 9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: Involvement of Bcl-2 and caspase-1
77. Cannabinoids enhance human B-cell growth at low nanomolar concentrations
78. 9-tetrahydrocannabinol
79. Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells
80. The genes encoding the peripheral cannabinoid receptor and α-L-fucosidase are located near a newly identified common virus integration site, Evi11
81. Retroviral insertions in Evi12, a novel common virus integration site upstream of Tra1/Grp94, frequently coincides with insertions in the gene encoding the peripheral cannabinoid receptor Cnr2
82. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines
83. Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60
84. Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation
85. 9-tetrahydrocannabinol is mediated by nuclear factor κB and CB1 cannabinoid receptor
86. 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-κB/Rel activation
87. Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation
88. Biosynthesis, uptake and degradation of anandamide and palmitoylethanolamide in leukocytes
89. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages
90. Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors
91. The peripheral cannabinoid receptor: Adenylate cyclase inhibition and G protein coupling
92. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase
93. (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase
94. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor
95. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation
96. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation
97. Involvement of the cAMP/protein kinase pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells
98. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells. Implications for cell proliferation and differentiation
99. An entourage effect: Inactive endogenous fatty acid glycerol esters enhance arachidonoyl-glycerol cannabinoid activity
100. 9-Tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism
101. Antineoplastic activity of cannabinoids
102. The inhibition of DNA synthesis by cannabinoids
103. Gene therapy for gliomas: Molecular targets, adenoviral vectors, and oncolytic viruses
104. Glioblastoma multiforme: The terminator
105. Δ-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway
106. Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro
107. A receptor alterations in the human basal ganglia in Huntington's disease
108. 9-tetrahydrocannabinol: A novel treatment for experimental autoimmune encephalomyelitis
109. Cannabinoids control spasticity and tremor in a multiple sclerosis model
110. Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for the degradation of endogenous oleamide and anandamide
111. Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid
112. Cytokine production in the brain following closed head injury: Dexanabinol (HU-211) is a novel TNFα inhibitor and an effective neuroprotectant
113. Developing cannabinoids as potential central nervous system agents
114. The non-psychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis